Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/60"
| Predicate | Value (sorted: none) |
|---|---|
| rdf:type | |
| rdf:type | |
| rdfs:label |
"evidence_1854"
|
| ?:Evidence_type | |
| ?:Evidence_enzyme_system | |
| ?:Evidence_numb_subjects | |
| ?:Evidence_object_dose | |
| ?:Evidence_precip_dose | |
| ?:Evidence_value | |
| dc:creator | |
| dc:date |
"06/05/2007 13:57:26"
|
| ?:content |
"Route of administration: oral
polymorphic enzyme: NO
study duration: 1 day petreatment with clarithromycin, single dose of triazolam
population: 6 male, 6 female
ages:21-39
AUC_i/AUC: 28.9/5.5ng/Ml*h
In a randomized, double-blind, 5-trial clinical pharmacokinetic-pharmacodynamic study, 12 volunteers received 0.125 mg triazolam orally, together with placebo, azithromycin, erythromycin, or clarithromycin....The effects of triazolam on dynamic measures were nearly identical when triazolam was given with placebo or azithromycin, but benzodiazepine agonist effects were enhanced during erythromycin and clarithromycin trials."
|
| rdfs:seeAlso |
All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl
The resource appears as object in one triple:
{ clarithromycin_increases_auc_triazolam, <http://purl.org/swan/1.2/swan-commons#citesAsSupportingEvidence>, evidence_1854 }